Terms: = Leukemia AND CREB3L1, 90993, Q96BA8, OASIS, ENSG00000157613
12 results:
1. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Decombis S; Bellanger C; Le Bris Y; Madiot C; Jardine J; Santos JC; Boulet D; Dousset C; Menard A; Kervoelen C; Douillard E; Moreau P; Minvielle S; Moreau-Aubry A; Tessoulin B; Roue G; Bidère N; Le Gouill S; Pellat-Deceunynck C; Chiron D
Blood; 2023 Nov; 142(18):1543-1555. PubMed ID: 37562004
[TBL] [Abstract] [Full Text] [Related]
2. Quantitation of Venetoclax in Human Plasma by High-Performance Liquid Chromatography with Ultraviolet Detection.
Fukuda N; Kobayashi T; Sato H; Akamine Y; Takahashi N; Miura M
J Chromatogr Sci; 2023 Dec; 62(1):58-64. PubMed ID: 36316274
[TBL] [Abstract] [Full Text] [Related]
3. Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.
Sumimoto T; Nakahara R; Suzuki Y; Tanaka R; Yoshida N; Ogata M; Itoh H
Ther Drug Monit; 2022 Jun; 44(3):419-429. PubMed ID: 34469417
[TBL] [Abstract] [Full Text] [Related]
4. creb3l1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms.
Morishita S; Yasuda H; Yamawaki S; Kawaji H; Itoh M; Edahiro Y; Imai M; Kogo Y; Tsuneda S; Ohsaka A; Hayashizaki Y; Ito M; Araki M; Komatsu N
Cancer Sci; 2021 Feb; 112(2):884-892. PubMed ID: 33280191
[TBL] [Abstract] [Full Text] [Related]
5. Sclerosing Epithelioid Fibrosarcoma: A Distinct Sarcoma With Aggressive Features.
Warmke LM; Meis JM
Am J Surg Pathol; 2021 Mar; 45(3):317-328. PubMed ID: 32769431
[TBL] [Abstract] [Full Text] [Related]
6. Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Puls F; Agaimy A; Flucke U; Mentzel T; Sumathi VP; Ploegmakers M; Stoehr R; Kindblom LG; Hansson M; Sydow S; Arbajian E; Mertens F
Am J Surg Pathol; 2020 May; 44(5):594-606. PubMed ID: 31913156
[TBL] [Abstract] [Full Text] [Related]
7. Paleo-oncology in the Dakhleh oasis, Egypt: Case studies and a paleoepidemiological perspective.
Molto E; Sheldrick P
Int J Paleopathol; 2018 Jun; 21():96-110. PubMed ID: 29499961
[TBL] [Abstract] [Full Text] [Related]
8. Simple Determination of Plasma Ponatinib Concentration Using HPLC.
Yasu T; Momo K; Kobayashi S; Kuroda S; Tojo A
Biol Pharm Bull; 2018 Feb; 41(2):254-258. PubMed ID: 29212964
[TBL] [Abstract] [Full Text] [Related]
9. A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection.
Sumimoto T; Nakahara R; Sato Y; Itoh H
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28374910
[TBL] [Abstract] [Full Text] [Related]
10. The most informative spacing test effectively discovers biologically relevant outliers or multiple modes in expression.
Pawlikowska I; Wu G; Edmonson M; Liu Z; Gruber T; Zhang J; Pounds S
Bioinformatics; 2014 May; 30(10):1400-8. PubMed ID: 24458951
[TBL] [Abstract] [Full Text] [Related]
11. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Furlong MT; Agrawal S; Hawthorne D; Lago M; Unger S; Krueger L; Stouffer B
J Pharm Biomed Anal; 2012 Jan; 58():130-5. PubMed ID: 21982905
[TBL] [Abstract] [Full Text] [Related]
12. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma.
Storlazzi CT; Mertens F; Nascimento A; Isaksson M; Wejde J; Brosjo O; Mandahl N; Panagopoulos I
Hum Mol Genet; 2003 Sep; 12(18):2349-58. PubMed ID: 12915480
[TBL] [Abstract] [Full Text] [Related]
